$0.83
0.0064[0.78%]
At close: Apr 23
$0.83
0[0.00%]
After Hours: 9:16AM EDT
Aligos Therapeutics
(NASDAQ:ALGS)Aligos Therapeutics Stock (NASDAQ:ALGS), Analyst Ratings, Price Targets, Predictions
Aligos Therapeutics Inc has a consensus price target of $6, established from looking at the 13 latest analyst ratings. The last 3 analyst ratings were released from Piper Sandler, Piper Sandler, and Jefferies on January 17, 2023, January 6, 2023, and January 6, 2023. With an average price target of $4.33 between Piper Sandler, Piper Sandler, and Jefferies, there's an implied 422.09% upside for Aligos Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
Jefferies
SVB Leerink
JP Morgan
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Aligos Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 01/17/2023 | ALGS | Buy Now | Aligos Therapeutics | $0.83 | 743.37% | Piper Sandler | Yasmeen Rahimi | $3 → $7 | Maintains | Overweight | Get Alert |
| 01/06/2023 | ALGS | Buy Now | Aligos Therapeutics | $0.83 | 261.45% | Piper Sandler | Yasmeen Rahimi | $2 → $3 | Upgrade | Neutral → Overweight | Get Alert |
| 01/06/2023 | ALGS | Buy Now | Aligos Therapeutics | $0.83 | 261.45% | Jefferies | Michael Yee | $2.5 → $3 | Upgrade | Hold → Buy | Get Alert |
| 11/03/2022 | ALGS | Buy Now | Aligos Therapeutics | $0.83 | 140.96% | SVB Leerink | Roanna Ruiz | $3 → $2 | Maintains | Market Perform | Get Alert |
| 05/05/2022 | ALGS | Buy Now | Aligos Therapeutics | $0.83 | 261.45% | SVB Leerink | Roanna Ruiz | $7 → $3 | Downgrade | Outperform → Market Perform | Get Alert |
| 03/23/2022 | ALGS | Buy Now | Aligos Therapeutics | $0.83 | 743.37% | SVB Leerink | Roanna Ruiz | $11 → $7 | Maintains | Outperform | Get Alert |
| 03/23/2022 | ALGS | Buy Now | Aligos Therapeutics | $0.83 | 381.93% | Piper Sandler | Yasmeen Rahimi | $15 → $4 | Downgrade | Overweight → Neutral | Get Alert |
| 03/11/2022 | ALGS | Buy Now | Aligos Therapeutics | $0.83 | 1707.23% | Piper Sandler | Yasmeen Rahimi | $47 → $15 | Maintains | Overweight | Get Alert |
| 03/11/2022 | ALGS | Buy Now | Aligos Therapeutics | $0.83 | 1225.3% | SVB Leerink | Roanna Ruiz | $10 → $11 | Maintains | Outperform | Get Alert |
| 02/16/2022 | ALGS | Buy Now | Aligos Therapeutics | $0.83 | 1104.82% | SVB Leerink | Roanna Ruiz | $15 → $10 | Maintains | Outperform | Get Alert |
| 01/07/2022 | ALGS | Buy Now | Aligos Therapeutics | $0.83 | 1345.78% | JP Morgan | Eric Joseph | $30 → $12 | Downgrade | Overweight → Neutral | Get Alert |
| 01/07/2022 | ALGS | Buy Now | Aligos Therapeutics | $0.83 | 1707.23% | SVB Leerink | Roanna Ruiz | $29 → $15 | Maintains | Outperform | Get Alert |
| 09/09/2021 | ALGS | Buy Now | Aligos Therapeutics | $0.83 | 3393.98% | SVB Leerink | Roanna Ruiz | — | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Aligos Therapeutics (ALGS)?
The latest price target for Aligos Therapeutics (NASDAQ: ALGS) was reported by Piper Sandler on January 17, 2023. The analyst firm set a price target for $7.00 expecting ALGS to rise to within 12 months (a possible 743.37% upside). 0 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Aligos Therapeutics (ALGS)?
The latest analyst rating for Aligos Therapeutics (NASDAQ: ALGS) was provided by Piper Sandler, and Aligos Therapeutics maintained their overweight rating.
When was the last upgrade for Aligos Therapeutics (ALGS)?
The last upgrade for Aligos Therapeutics Inc happened on January 6, 2023 when Piper Sandler raised their price target to $3. Piper Sandler previously had a neutral for Aligos Therapeutics Inc.
When was the last downgrade for Aligos Therapeutics (ALGS)?
The last downgrade for Aligos Therapeutics Inc happened on May 5, 2022 when SVB Leerink changed their price target from $7 to $3 for Aligos Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Aligos Therapeutics (ALGS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aligos Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aligos Therapeutics was filed on January 17, 2023 so you should expect the next rating to be made available sometime around January 17, 2024.
Is the Analyst Rating Aligos Therapeutics (ALGS) correct?
While ratings are subjective and will change, the latest Aligos Therapeutics (ALGS) rating was a maintained with a price target of $3.00 to $7.00. The current price Aligos Therapeutics (ALGS) is trading at is $0.83, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.